文献速递主动脉疾病

远程肾脏缺血预处理降低开窗式主动脉瘤腔内修复术后肾病风险的前瞻性随机试验

A prospective randomized trial of remote renal ischemic preconditioning for reducing nephropathy risk following fenestrated endovascular aortic aneurysm repair.
PubMed 文献 · J Vasc Surg · 2025-02-25

该单中心、盲法、前瞻性随机试验纳入80例择期行开窗式腔内主动脉瘤修复术(FEVAR)的肾旁主动脉瘤患者,评估通过手动充气臂部血压袖带造成上肢缺血进行远程肾脏缺血预处理的效果。结果显示30天急性肾损伤(AKI)总体发生率为11.3%,组间无差异,2年免于肾功能下降率组间亦无差异(56.2% vs 81.1%,log-rank P = .12)。结论认为该干预未带来30天AKI、死亡或长期肾脏保护获益。

要点

  • 远程肾脏缺血预处理未降低择期FEVAR术后30天AKI发生率。
  • 2年免于肾功能下降率治疗组56.2% vs 对照组81.1%,log-rank P = .12,无统计学差异。
  • 30天AKI总体发生率为11.3%(风险期7.5%、损伤期2.5%、衰竭期1.3%),组间无差异。

核心结论

  • 采用上肢缺血的远程肾脏缺血预处理在择期FEVAR患者中未提供30天AKI、死亡或长期肾脏保护获益。

研究设计与样本

  • 单中心、盲法、前瞻性随机试验,纳入80例于2018年7月至2023年8月期间择期使用Cook ZFEN装置行FEVAR的患者(80%男性;平均动脉瘤直径6.1 cm)。
  • 干预为通过手动充气臂部血压袖带造成上肢缺血进行远程肾脏缺血预处理。
  • 研究把握度设定为检测肾脏损伤发生率>25%的差异。

主要发现

  • 30天随访率95.0%,平均随访时长20.2 ± 14.6个月。
  • 治疗组年龄有更大趋势(77.4 ± 7.8岁 vs 74.1 ± 7.0岁),但未达统计学显著(P = .05)。
  • 平均基线估算肾小球滤过率为69.8 ± 21.0 mL/min/1.73 m2,平均肌酐为1.1 ± 0.4 mg/dL,30.0%患者慢性肾脏病分期≥3。
  • 30天AKI总体发生率为11.3%(风险期7.5%、损伤期2.5%、衰竭期1.3%),组间无差异;无30天死亡。
  • 2年免于肾功能下降率组间无差异(56.2% vs 81.1%;log-rank P = .12)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: We sought to evaluate whether remote renal ischemic preconditioning is effective for reducing postoperative acute kidney injury (AKI) and mid-term renal function decline in patients undergoing elective fenestrated endovascular aneurysm repair (FEVAR) of juxtarenal aortic aneurysms. METHODS: We performed a single-site, blinded, prospective randomized trial of a renal ischemic preconditioning intervention using arm ischemia via manual inflation of arm blood pressure cuff. We evaluated 30-day AKI, determined using the Risk, Injury, Failure, loss of Function, and End-stage (RIFLE) classification and 2-year freedom from renal function decline, defined as a >30% decrease in baseline estimated glomerular function rate. The study was powered to detect a >25% difference in renal injury incidence. RESULTS: We enrolled 80 patients (80% male; mean aneurysm diameter, 6.1 cm) who were undergoing elective FEVAR using Cook ZFEN devices between July 2018 and August 2023. The 30-day follow-up rate was 95.0%, and mean follow-up duration was 20.2 ± 14.6 months. Although there was a trend to older patient age in the treatment group (77.4 ± 7.8 years vs 74.1 ± 7.0 years), this difference did not reach statistical significance (P = .05). The mean baseline estimated glomerular function rate and creatinine were 69.8 ± 21.0 mL/min/1.73 m2 and 1.1 ± 0.4 mg/dL respectively, and 30.0% had chronic kidney disease stage ≥3. There were no differences in any other baseline or operative metrics between the groups. The rate of AKI at 30 days was 11.3% overall (risk, 7.5%; injury, 2.5%; failure, 1.3%) and did not differ between groups. There were no 30-day deaths. There was no difference in 2-year freedom from renal function decline between treatment groups (56.2% vs 81.1%; log-rank P = .12). CONCLUSIONS: Renal ischemic preconditioning using arm ischemia did not confer a 30-day AKI or mortality or long-term renal protection benefit in patients undergoing elective FEVAR.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Tran K, Dossabhoy S, Adkar S, et al. A prospective randomized trial of remote renal ischemic preconditioning for reducing nephropathy risk following fenestrated endovascular aortic aneurysm repair. J Vasc Surg. 2025. PMID: 40015607. doi:10.1016/j.jvs.2025.02.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。